Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Current Assets (2021 - 2025)

Historic Current Assets for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $36.3 million.

  • Verrica Pharmaceuticals' Current Assets rose 2869.41% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.3 million, marking a year-over-year increase of 2869.41%. This contributed to the annual value of $51.2 million for FY2024, which is 3398.81% down from last year.
  • Per Verrica Pharmaceuticals' latest filing, its Current Assets stood at $36.3 million for Q3 2025, which was up 2869.41% from $36.8 million recorded in Q2 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Current Assets ranged from a high of $102.0 million in Q1 2021 and a low of $28.2 million during Q3 2024
  • In the last 5 years, Verrica Pharmaceuticals' Current Assets had a median value of $57.3 million in 2022 and averaged $60.4 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 11137.23% in 2023, then crashed by 6927.01% in 2024.
  • Quarter analysis of 5 years shows Verrica Pharmaceuticals' Current Assets stood at $74.3 million in 2021, then crashed by 47.38% to $39.1 million in 2022, then skyrocketed by 98.21% to $77.5 million in 2023, then plummeted by 33.99% to $51.2 million in 2024, then fell by 29.12% to $36.3 million in 2025.
  • Its last three reported values are $36.3 million in Q3 2025, $36.8 million for Q2 2025, and $39.5 million during Q1 2025.